- Home
- ESPR vs INBK Comparison
ESPR vs INBK Comparison
Compare ESPR & INBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- INBK
- Stock Information
- Founded
- ESPR 2008
- INBK 1999
- Country
- ESPR United States
- INBK United States
- Employees
- ESPR N/A
- INBK N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- INBK Major Banks
- Sector
- ESPR Health Care
- INBK Finance
- Exchange
- ESPR Nasdaq
- INBK Nasdaq
- Market Cap
- ESPR 399.0M
- INBK 363.3M
- IPO Year
- ESPR 2013
- INBK N/A
- Fundamental
- Price
- ESPR $2.32
- INBK $37.42
- Analyst Decision
- ESPR Buy
- INBK Buy
- Analyst Count
- ESPR 5
- INBK 4
- Target Price
- ESPR $7.30
- INBK $41.13
- AVG Volume (30 Days)
- ESPR 8.5M
- INBK 25.7K
- Earning Date
- ESPR 11-07-2024
- INBK 01-22-2025
- Dividend Yield
- ESPR N/A
- INBK 0.65%
- EPS Growth
- ESPR N/A
- INBK 114.10
- EPS
- ESPR N/A
- INBK 2.53
- Revenue
- ESPR $295,451,000.00
- INBK $108,980,000.00
- Revenue This Year
- ESPR $186.90
- INBK N/A
- Revenue Next Year
- ESPR $31.10
- INBK $16.32
- P/E Ratio
- ESPR N/A
- INBK $14.81
- Revenue Growth
- ESPR 187.12
- INBK 26.53
- 52 Week Low
- ESPR $1.58
- INBK $23.05
- 52 Week High
- ESPR $3.94
- INBK $43.26
- Technical
- Relative Strength Index (RSI)
- ESPR 45.30
- INBK 40.35
- Support Level
- ESPR $2.12
- INBK $36.34
- Resistance Level
- ESPR $2.54
- INBK $41.10
- Average True Range (ATR)
- ESPR 0.33
- INBK 1.68
- MACD
- ESPR -0.09
- INBK -0.58
- Stochastic Oscillator
- ESPR 22.86
- INBK 25.14
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.